Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report

RATIONALE: Pyrotinib is a novel dual pan-ErbB receptor tyrosine kinase inhibitor, approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, there was still limited information regarding specific effect of pyrotinib on HER2-positiv...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicine (Baltimore)
Main Authors: Dai, Jiali, Chen, Yuetong, Tang, Cuiju, Wei, Xiaowei, Gong, Yang, Wei, Jingsun, Gu, Dongying, Chen, Jinfei
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2020
Teme:
5750
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310977/
https://ncbi.nlm.nih.gov/pubmed/32569228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000020809
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki